Published in Infect Immun on January 01, 1988
Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 2.81
Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med (1991) 2.64
T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun (1991) 2.17
Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest (2010) 1.67
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother (2004) 1.46
Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother (2000) 1.42
Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes. Infect Immun (2002) 1.31
The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob Agents Chemother (1997) 1.24
Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med (2014) 1.18
Effect of polysaccharide capsule and methods of preparation on human lymphocyte proliferation in response to Cryptococcus neoformans. Infect Immun (1993) 1.15
The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect Immun (1999) 1.11
Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation. Infect Immun (1989) 0.99
The cell wall and membrane of Cryptococcus neoformans possess a mitogen for human T lymphocytes. Infect Immun (1999) 0.96
Phagocytosis and protein processing are required for presentation of Cryptococcus neoformans mitogen to T lymphocytes. Infect Immun (2000) 0.95
Proteins in the cell wall and membrane of Cryptococcus neoformans stimulate lymphocytes from both adults and fetal cord blood to proliferate. Infect Immun (1996) 0.91
Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients. J Immunol (2008) 0.80
Tacrolimus Increases the Effectiveness of Itraconazole and Fluconazole against Sporothrix spp. Front Microbiol (2017) 0.75
Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions (1976) 9.68
Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology (1977) 7.10
Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol (1981) 4.31
Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 4.25
Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med (1986) 3.34
New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother (1984) 2.32
Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med (1984) 2.03
Abnormalities in cell-mediated immunity in patients with Cryptococcus neoformans infection. J Allergy Clin Immunol (1975) 1.99
Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines. Immunology (1983) 1.99
Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun (1980) 1.77
Suppressive effect of cyclosporin A on the development of Leishmania tropica-induced lesions in genetically susceptible BALB/c mice. J Immunol (1986) 1.43
Antimalarial activity of cyclosporin A. Agents Actions (1981) 1.33
Granulocyte-alveolar-macrophage interaction in the pulmonary clearance of Staphylococcus aureus. Am Rev Respir Dis (1983) 1.24
Differential effect of cyclosporin A on the expression of T and B lymphocyte activation antigens. J Immunol (1984) 1.20
Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun (1985) 1.19
Cyclosporin A inhibits the delayed-type hypersensitivity reaction: impaired production of early pro-inflammatory mediator(s). Eur J Immunol (1984) 1.09
Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major. J Immunol (1986) 1.05
Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo. Antimicrob Agents Chemother (1983) 1.04
Antischistosomal effect of cyclosporin A: cure and prevention of mouse and rat schistosomiasis mansoni. Infect Immun (1986) 0.98
Cyclosporine: a review of drug monitoring problems and presentation of a simple, accurate liquid chromatographic procedure that solves these problems. Clin Biochem (1986) 0.95
Filaricidal effects of cyclosporin-A against Dipetalonema viteae in Mastomys natalensis. Trans R Soc Trop Med Hyg (1984) 0.93
Cyclosporine: experience with therapeutic monitoring. Ther Drug Monit (1984) 0.91
Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis. Clin Immunol Immunopathol (1986) 0.84
T-cell-independent macrophage activation in mice induced with rRNA from Listeria monocytogenes and dimethyldioctadecylammonium bromide. Infect Immun (1986) 0.80
Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest (1990) 5.21
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol (1980) 4.00
A Legionella pneumophila gene encoding a species-specific surface protein potentiates initiation of intracellular infection. Infect Immun (1989) 3.18
Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med (1991) 2.64
Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax (2003) 2.54
Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun (1997) 2.54
CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J Immunol (2000) 2.43
Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med (1998) 2.43
Protection from pulmonary fibrosis in the absence of CCR2 signaling. J Immunol (2001) 2.38
The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection. J Immunol (1995) 2.37
Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am J Med (2001) 2.35
Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J Immunol (1990) 2.28
The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol (1994) 2.20
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun (1991) 2.17
Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol (1996) 2.12
IL-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol (1998) 1.93
The accessory cell function of human alveolar macrophages in specific T cell proliferation. J Immunol (1984) 1.81
Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol (1995) 1.80
Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect Immun (2001) 1.76
Characterization of accessory molecules in murine lung dendritic cell function: roles for CD80, CD86, CD54, and CD40L. Am J Respir Cell Mol Biol (1997) 1.72
IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am J Respir Cell Mol Biol (1997) 1.71
Eosinophils are a major source of nitric oxide-derived oxidants in severe asthma: characterization of pathways available to eosinophils for generating reactive nitrogen species. J Immunol (2001) 1.69
Cutting edge: Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol (1999) 1.69
Characterization of murine lung dendritic cells: similarities to Langerhans cells and thymic dendritic cells. J Exp Med (1990) 1.65
The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis (1979) 1.61
Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am J Respir Cell Mol Biol (1995) 1.59
GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol (2000) 1.58
The role of methotrexate in the management of steroid-dependent asthma. Chest (1994) 1.46
Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity. Am J Respir Cell Mol Biol (1991) 1.45
Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest (1996) 1.45
The role of macrophage inflammatory protein-1 alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection. J Immunol (2000) 1.39
Macrophage inflammatory protein-1alpha (MIP-1alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J Immunol (1997) 1.39
Natural and perturbed distributions of Langerhans cells: responses to ultraviolet light, heterotopic skin grafting, and dinitrofluorobenzene sensitization. J Invest Dermatol (1980) 1.39
Corneal allografts fail to express Ia antigens. Nature (1979) 1.38
Experimental murine pulmonary cryptococcosis. Differences in pulmonary inflammation and lymphocyte recruitment induced by two encapsulated strains of Cryptococcus neoformans. Lab Invest (1994) 1.37
Effect of granulocyte-macrophage colony-stimulating factor on rat alveolar macrophage anticryptococcal activity in vitro. J Immunol (1994) 1.36
Expression of VCAM-1 and E-selectin in an in vivo model of endothelial activation. Am J Pathol (1993) 1.35
Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am J Pathol (1987) 1.34
Impaired functional activity of alveolar macrophages from GM-CSF-deficient mice. Am J Physiol Lung Cell Mol Physiol (2001) 1.33
Legionella pneumophila replicates within rat alveolar epithelial cells. J Infect Dis (1993) 1.32
Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent. Am J Pathol (1999) 1.28
A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol (1995) 1.28
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J (2010) 1.26
Granulocyte-alveolar-macrophage interaction in the pulmonary clearance of Staphylococcus aureus. Am Rev Respir Dis (1983) 1.24
Immune enhancement of pulmonary clearance of nontypable Haemophilus influenzae. Infect Immun (1988) 1.23
Regulatory effects of macrophage inflammatory protein 1alpha/CCL3 on the development of immunity to Cryptococcus neoformans depend on expression of early inflammatory cytokines. Infect Immun (2001) 1.22
Cells and cytokines in pulmonary cryptococcosis. Res Immunol (1998) 1.21
Human alveolar macrophages: HLA-DR-positive macrophages that are poor stimulators of a primary mixed leukocyte reaction. J Immunol (1986) 1.20
Antigen presentation by guinea pig alveolar macrophages. J Immunol (1981) 1.19
Mononuclear cells in human lung parenchyma. Characterization of a potent accessory cell not obtained by bronchoalveolar lavage. Am Rev Respir Dis (1987) 1.18
Effect of systemic immunization on pulmonary clearance of Haemophilus influenzae type b. Infect Immun (1985) 1.16
Role for C5 and neutrophils in the pulmonary intravascular clearance of circulating Cryptococcus neoformans. Am J Respir Cell Mol Biol (1993) 1.14
Alterations in the pattern of arachidonate metabolism accompany rat macrophage differentiation in the lung. J Immunol (1990) 1.14
Langerhans cells: sentinels of skin associated lymphoid tissue. J Invest Dermatol (1980) 1.12
Postmortem diagnosis of acute anaphylaxis by serum tryptase analysis. A case report. Am J Clin Pathol (1993) 1.12
Treatment of murine cryptococcosis with cyclosporin-A in normal and athymic mice. Am Rev Respir Dis (1989) 1.12
Depletion of murine CD8+ T cells in vivo decreases pulmonary clearance of a moderately virulent strain of Cryptococcus neoformans. J Lab Clin Med (1993) 1.12
Role of diminished epithelial GM-CSF in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2000) 1.10
CD8 cells play a critical role in delayed type hypersensitivity to intact Cryptococcus neoformans. J Immunol (1994) 1.10
Inability of human alveolar macrophages to stimulate resting T cells correlates with decreased antigen-specific T cell-macrophage binding. J Immunol (1986) 1.09
Comparison of lung dendritic cells and B cells in stimulating naive antigen-specific T cells. J Immunol (1999) 1.05
Different patterns of arachidonate metabolism in autologous human blood monocytes and alveolar macrophages. J Immunol (1989) 1.05
The role of C5 in polymorphonuclear leukocyte recruitment in response to Streptococcus pneumoniae. Am Rev Respir Dis (1984) 1.04
Immunohistochemical detection of human basophils in postmortem cases of fatal asthma. Am J Respir Crit Care Med (2001) 1.03
Natural killer cell function in human lung is compartmentalized. Am Rev Respir Dis (1987) 1.02
Androstenedione metabolism in human alveolar macrophages. J Clin Endocrinol Metab (1983) 1.02
Separation of potent and poorly functional human lung accessory cells based on autofluorescence. J Leukoc Biol (1989) 1.02
Alveolar macrophages in pulmonary immune responses. I. Role in the initiation of primary immune responses and in the selective recruitment of T lymphocytes to the lung. J Immunol (1983) 1.02
Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21. Eur Respir J (2007) 1.01
The migration of bronchoalveolar macrophages into hilar lymph nodes. Am J Pathol (1984) 1.01
Dissociation of airway hyperresponsiveness from immunoglobulin E and airway eosinophilia in a murine model of allergic asthma. Am J Respir Cell Mol Biol (1999) 0.99
Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia. J Clin Pathol (2006) 0.99
Role of C5 and recruited neutrophils in early clearance of nontypable Haemophilus influenzae from murine lungs. Infect Immun (1985) 0.99
Leukocyte recruitment during pulmonary Cryptococcus neoformans infection. Immunopharmacology (2000) 0.99
Specific binding of T lymphocytes to macrophages. I. Kinetics of binding. J Immunol (1977) 0.99
Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J Clin Pathol (2004) 0.99
Mechanisms of complement-mediated clearance of bacteria from the murine lung. Am Rev Respir Dis (1982) 0.98
Alveolar epithelial cells block lymphocyte proliferation in vitro without inhibiting activation. Am J Respir Cell Mol Biol (1991) 0.98
Pulmonary clearance of encapsulated and unencapsulated Haemophilus influenzae strains. Infect Immun (1984) 0.98
Bronchoalveolar cells from sarcoid patients demonstrate enhanced antigen presentation. J Immunol (1985) 0.97
In vivo depletion of murine CD8 positive T cells impairs survival during infection with a highly virulent strain of Cryptococcus neoformans. Mycopathologia (1994) 0.96
TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation. Histochem Cell Biol (2008) 0.96
Differentiation-related expression of ICAM-1 by rat alveolar epithelial cells. Am J Respir Cell Mol Biol (1993) 0.94
Human pulmonary macrophages. Functional comparison of cells obtained from whole lung and by bronchoalveolar lavage. Am Rev Respir Dis (1986) 0.93
Specific binding of T lymphocytes to macrophages IV. Dependence on cations, temperature and cytochalasin B-sensitive mechanisms. Eur J Immunol (1979) 0.93
Increased salivary elastase precedes gram-negative bacillary colonization in postoperative patients. Am Rev Respir Dis (1987) 0.92